Psoriatic Disease

Patients with psoriasis who switched from Humira to adalimumab biosimilars for nonmedical reasons had similar drug retention as those who stayed on the originator, according to a study.

Clinicians should consider the heterogeneity of psoriatic arthritis when selecting therapeutic options, according to a speaker at the ACR State-of-the-Art Clinical Symposium.

Although the overall incidence of psoriatic arthritis in the United States remained stable from 2000 to 2017, there was a 3% per-year increase among women during this time, according to data published in Arthritis & Rheumatology.

A daily 30 mg dose of upadacitinib — but not the 15 mg dose — is superior to adalimumab at improving the signs and symptoms of psoriatic arthritis among patients with inadequate response to non-biologic disease-modifying antirheumatic drugs.

Anxiety and depression symptoms reduce the likelihood of achieving sustained minimal disease activity in psoriatic arthritis, according to data published in Arthritis Care & Research.

Patients on methotrexate for psoriasis or psoriatic arthritis were more likely to develop liver complications than those taking it for rheumatoid arthritis, according to a study.

The FDA has extended its review period for the supplemental new drug application of AbbVie’s upadacitinib for active psoriatic arthritis to allot more time to examine its risk-benefit profile, according to a company press release.

Joel M. Gelfand, MD, MSCE, professor of dermatology and epidemiology at the University of Pennsylvania, discusses an upcoming program from the National Heart, Lung, and Blood Institute.

Systemic inflammation burden and disease activity are independent risk factors for heart failure among patients with psoriatic disease, according to data published in Arthritis Care & Research.

Men with poor cardiorespiratory fitness levels during late adolescence were more likely to develop psoriasis or psoriatic arthritis later in life, according to a study.